Vaxess Technologies Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Employees
  • 27
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $25.3M
Latest Deal Amount
  • Investors
  • 16

Vaxess Technologies General Information

Description

Developer of novel therapies designed to help in oncology care and infectious diseases. The company's therapies provide long-term cancer immunity, clearance of distant tumors, and compatibility with antigens, enabling healthcare practitioners to improve patient outcomes with decreased treatment burdens.

Contact Information

Website
www.vaxess.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Drug Discovery
Pharmaceuticals
Biotechnology
Primary Office
  • 790 Memorial Drive
  • Suite 200
  • Cambridge, MA 02139
  • United States
+1 (614) 000-0000

Vaxess Technologies Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Vaxess Technologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
15. Later Stage VC (Series B) 14-May-2021 $25.3M 000.00 000.00 Completed Generating Revenue
14. Grant 22-Apr-2021 00.000 00.00 Completed Generating Revenue
13. Debt - PPP 30-Apr-2020 00.00 Completed Generating Revenue
12. Later Stage VC (Series A) 27-Jun-2019 00.000 00.00 00.00 Completed Generating Revenue
11. Grant 01-Jan-2019 00000 00.000 Completed Generating Revenue
10. Grant 09-Oct-2018 000 00.000 Completed Generating Revenue
9. Early Stage VC (Series A3) 09-Jan-2017 00000 00.000 000.00 Completed Generating Revenue
8. Grant 01-Nov-2016 000 00.000 Completed Generating Revenue
7. Grant 21-Oct-2016 $1.53M $4.75M Completed Generating Revenue
6. Accelerator/Incubator 13-Oct-2016 $4.75M Completed Generating Revenue
To view Vaxess Technologies’s complete valuation and funding history, request access »

Vaxess Technologies Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 000,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A4 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A3 000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A2 1,114,201 $0.000100 $1.12 $1.12 1x $0.13 4.81%
Series A1 226,405 $0.000100 $1.12 $1.12 1x $0.13 0.98%
To view Vaxess Technologies’s complete cap table history, request access »

Vaxess Technologies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel therapies designed to help in oncology care and infectious diseases. The company's therapies provide
Discovery Tools (Healthcare)
Cambridge, MA
27 As of 2021
000.00
00.00 0000-00-00
00000000000 000.00

00000

giat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deser
0000 000000000
Cambridge, United Kingdom
000 As of 0000
00000
0.000 0000-00-00
000000&0 00000

0000000

orem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore e
0000 000000000
Cambridge, United Kingdom
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vaxess Technologies Competitors (48)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kymab Formerly VC-backed Cambridge, United Kingdom 000 00000 000000&0 00000
0000000 0000000000 Venture Capital-Backed Cambridge, United Kingdom 00 00000 00000000000 00000
00000 000000000000 Venture Capital-Backed Oxfordshire, United Kingdom 00 00000 0000000000 0 00000
000000 0000000000 Accelerator/Incubator Backed Atlanta, GA 00 0000000000
00000000 Private Equity-Backed Holliston, MA 00 000.00 000000000 - 000.00
You’re viewing 5 of 48 competitors. Get the full list »

Vaxess Technologies Executive Team (15)

Name Title Board Seat Contact Info
Michael Schrader Co-Founder, Chief Executive Officer & Board Member
Mark Tracy Chief Technology Officer
Kathryn Kosuda Ph.D Co-Founder, Chief Scientific Officer, Vice President of Research & Development & Board Member
Ted Hibben Chief Business Officer
David Kaplan Ph.D Scientific Co-Founder & Advisor
You’re viewing 5 of 15 executive team members. Get the full list »

Vaxess Technologies Board Members (8)

Name Representing Role Since
Aaron Sandoski Norwich Ventures Board Member 000 0000
Ann DeWitt Ph.D Self Board Member 000 0000
Johannes Fruehauf Ph.D Mission BioCapital Board Member 000 0000
Kathryn Kosuda Ph.D Vaxess Technologies Co-Founder, Chief Scientific Officer, Vice President of Research & Development & Board Member 000 0000
Michael Schrader Vaxess Technologies Co-Founder, Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Vaxess Technologies Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vaxess Technologies Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
The Engine Venture Capital Minority 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
Bill & Melinda Gates Foundation Not-For-Profit Venture Capital Minority 000 0000 000000 0
National Cancer Institute Government 000 0000 000000 0
National Institute for Environmental Health and Safety Government 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »